BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15713516)

  • 1. Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?
    Meert AP; Martin B; Verdebout JM; Noël S; Ninane V; Sculier JP
    Lung Cancer; 2005 Mar; 47(3):325-36. PubMed ID: 15713516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
    Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
    Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
    Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
    Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
    Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
    Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
    Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased survival in EGFR gene amplified vulvar carcinoma.
    Growdon WB; Boisvert SL; Akhavanfard S; Oliva E; Dias-Santagata DC; Kojiro S; Horowitz NS; Iafrate AJ; Borger DR; Rueda BR
    Gynecol Oncol; 2008 Nov; 111(2):289-97. PubMed ID: 18768215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR gene and protein expression in breast cancers.
    Park K; Han S; Shin E; Kim HJ; Kim JY
    Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
    Kimura M; Tsuda H; Morita D; Shinto E; Tanimoto T; Ichikura T; Mochizuki H; Matsubara O
    Jpn J Clin Oncol; 2005 Jun; 35(6):324-31. PubMed ID: 15928192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study.
    Hirashima N; Takahashi W; Yoshii S; Yamane T; Ooi A
    Mod Pathol; 2001 Jun; 14(6):556-62. PubMed ID: 11406656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
    Dacic S; Flanagan M; Cieply K; Ramalingam S; Luketich J; Belani C; Yousem SA
    Am J Clin Pathol; 2006 Jun; 125(6):860-5. PubMed ID: 16690485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.